Table 1 Clinical, virological and histological patient features.
From: Chronic hepatitis C liver microenvironment: role of the Th17/Treg interplay related to fibrogenesis
Chronic HCV Patients (n = 27) | ||
|---|---|---|
Age (ys) median (range) | 53 (32–72) | |
Sex | Male % (n) | 51.9 (14) |
Risk factor for HCV infection % (n) | Drug abuse | 14.8 (4) |
Transfusion | 22.2 (6) | |
Sexual | 11.1 (3) | |
Haemodialysis | 3.7 (1) | |
Occupational | 3.7 (1) | |
Tattoos | 3.7 (1) | |
Unknown | 3.7 (11) | |
Genotype % (n) | 1a | 33.3(9) |
1b | 44.4 (12) | |
2 | 3.7 (1) | |
3a | 7.4 (2) | |
ND | 11.1 (3) | |
Viral load (IU/ml) median | 888,240 | |
(range) | (12,535–9,070,000) | |
ALT (IU/L) median (range) | 82 (23–254) | |
% (n) | Elevated | 92.6 (25) |
AST (IU/L) median (range) | 64.5 (22–234) | |
% (n) | Elevated | 81.5 (22) |
Hepatitis % (n) | Minimal | 3.70 (1) |
Mild | 18.52 (5) | |
Moderate | 62.96 (17) | |
Severe | 14.82 (4) | |
Fibrosis stage1% (n) | Significant Fibrosis (≥2) | 62.96 (17) |
Advanced Fibrosis (≥3) | 37.04 (10) |
